The Classic Egg-Yolk Macular Dystrophy of Childhood
The moon doesn't simply switch between full and new — it travels through a whole sequence of recognisable phases in between, each one a distinct, predictable stage in a longer cycle rather than a sudden jump. Best disease moves through beneath the macula in a rather similar way: a rounded, golden-yellow deposit begins as a smooth, whole shape, gradually breaks apart over years, and eventually settles into its final form. Vitelliform, a name borrowed from the Latin word for egg yolk, describes nothing more than the early appearance of that deposit — and it's this whole gradual sequence, rather than any one symptom, that dictates how the condition gets tracked over the years.
Something that often catches Rwandan families off guard at the first visit: a child's lesion can look dramatic on examination, egg-yolk shaped and unmistakable, and yet reading stays completely comfortable for their age. How dramatic a lesion looks and how well a person actually sees aren't necessarily linked, which is exactly why getting the staging right outweighs reacting to a striking retinal photograph.
In stage one, before the lesion has broken apart, sight often stays close to normal — a child can have an unmistakable finding on the retina and still see perfectly fine. Trouble tends to start once that smooth deposit fractures, something clinicians routinely compare to a cracked egg; reading gets harder, and central vision turns blurred or slightly warped around this point. Later stages tend to lock in whatever vision loss has already happened rather than keep worsening steadily, though a small share of patients experience one further, sudden drop if stray new blood vessels form beneath the retina.
BEST1 is the gene involved. Working correctly, it builds bestrophin-1, a protein that manages how ions and fluid cross the retinal pigment epithelium. When that process fails, fluid and pigment pool in the wrong place under the macula, slowly forming into what becomes the visible lesion. Passed on as a dominant trait, it doesn't behave consistently from person to person — one relative might carry an obvious lesion and notice nothing at all, while another with the identical mutation ends up with real, measurable vision loss.
The electro-oculogram usually gives the clearest answer, since it reliably comes back abnormal — showing a low Arden ratio — even when a standard ERG from the same eye reads as entirely normal. That gap between the two results is exactly what steers a specialist toward Best disease rather than a condition that only resembles it. Tracking the lesion through repeat OCT scans over several visits shows how it's actually progressing, and a positive BEST1 test both confirms the diagnosis and flags relatives who might be silently carrying the same fault.
Since this lesion is fully capable of sitting unchanged for years, doctors generally lean toward careful observation rather than rushing into treatment, all while watching for the modest chance of abnormal vessel growth as things slowly evolve. Only once vision genuinely starts slipping does regenerative stem cell therapy become part of the conversation, aimed at holding on to whatever central vision is still functioning.
Indeed, and this is actually a familiar, reassuring pattern seen in the early stage of Best disease. The size of a lesion in a photograph tells us remarkably little about actual visual function, which is exactly why careful staging matters far more than a dramatic-looking image.
No — it stays entirely local and benign, confined to the retina, with absolutely no connection to cancer. It does pass through a documented sequence of stages as time goes on, and tracking that exact sequence is the whole reason behind our continued monitoring.
It comes down to variable expressivity, a trait BEST1 mutations are well known for producing. She could easily carry the identical faulty gene without it ever producing a visible lesion or symptoms — testing her directly is the only way to know for certain rather than assuming she's been spared.
No, certainly not for everyone — a fair share of patients keep solid central vision for years on end, especially when their lesion stalls at an earlier stage. Because the trajectory genuinely varies between individuals, staying on top of monitoring is what lets us act quickly the instant something actually changes.